We are live on ! Find out more
VIVO

Meridian Bioscience Inc

Delisted

VIVO was delisted on the 30th of January, 2023.

173 hedge funds and large institutions have $462M invested in Meridian Bioscience Inc in 2019 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 53 increasing their positions, 51 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

152% more call options, than puts

Call options by funds: $569K | Put options by funds: $226K

4% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 51

5% less funds holding

Funds holding: 183173 (-10)

15% less first-time investments, than exits

New positions opened: 34 | Existing positions closed: 40

34% less capital invested

Capital invested by funds: $701M → $462M (-$239M)

Holders
173
Holders Change
-10
Holders Change %
-5.46%
% of All Funds
3.76%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
34
Increased
53
Reduced
51
Closed
40
Calls
$569K
Puts
$226K
Net Calls
+$343K
Net Calls Change
-$1.58M
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$76.7M +$1.69M +140,424 +2%
Vanguard Group
2
Vanguard Group
Pennsylvania
$54.3M +$102K +8,459 +0.2%
BCM
3
Brown Capital Management
Maryland
$42.8M -$304K -25,218 -0.7%
Renaissance Technologies
4
Renaissance Technologies
New York
$35.1M -$615K -51,048 -2%
Dimensional Fund Advisors
5
Dimensional Fund Advisors
Texas
$23.1M +$295K +24,483 +1%
State Street
6
State Street
Massachusetts
$19.7M +$1.18M +97,933 +6%
SFM
7
Systematic Financial Management
New Jersey
$14.2M +$539K +44,769 +4%
Norges Bank
8
Norges Bank
Norway
$13M -$2.09M -173,339 -14%
PP
9
Prudential plc
United Kingdom
$12.5M
Geode Capital Management
10
Geode Capital Management
Massachusetts
$10.5M +$562K +46,640 +6%
Assenagon Asset Management
11
Assenagon Asset Management
Luxembourg
$8.47M +$8.58M +712,589 New
Ameriprise
12
Ameriprise
Minnesota
$8.35M +$2.49M +207,104 +42%
D.E. Shaw & Co
13
D.E. Shaw & Co
New York
$7.36M +$2.83M +235,171 +61%
Northern Trust
14
Northern Trust
Illinois
$6.77M -$334K -27,733 -5%
Bank of New York Mellon
15
Bank of New York Mellon
New York
$6.46M -$1.91M -158,915 -23%
Goldman Sachs
16
Goldman Sachs
New York
$5.91M +$900K +74,698 +18%
Charles Schwab
17
Charles Schwab
California
$5.07M -$1.56M -129,628 -23%
Wells Fargo
18
Wells Fargo
California
$4.74M +$65.1K +5,402 +1%
Invesco
19
Invesco
Georgia
$4.6M -$1.22M -100,944 -21%
Principal Financial Group
20
Principal Financial Group
Iowa
$4.3M +$69.4K +5,757 +2%
Acadian Asset Management
21
Acadian Asset Management
Massachusetts
$3.8M +$2.77M +230,299 +256%
Marshall Wace
22
Marshall Wace
United Kingdom
$3.72M +$2.79M +231,721 +285%
N
23
Nuveen
North Carolina
$3.25M +$3.3M +273,681 New
OAM
24
Oxford Asset Management
United Kingdom
$3.21M +$1.12M +92,900 +53%
JP Morgan Chase
25
JP Morgan Chase
New York
$2.63M -$499K -41,446 -16%

VIVO Hedge Fund Activity: Q2 2019 in Review

173 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Meridian Bioscience Inc (VIVO) for Q2 2019, worth a combined $462M — down 34% from $701M a quarter earlier.

Sellers outnumbered buyers: 40 funds closed out of VIVO and 34 opened new positions — a net loss of 6 holders — while 51 trimmed existing stakes and 53 added.

The largest buyer was Assenagon Asset Management, opening a new position worth an estimated $8.58M. The largest seller was Vaughan Nelson Investment Management, exiting entirely with an estimated $25.8M sold.

  • 173 institutional investors held Meridian Bioscience Inc (VIVO) as of Q2 2019, down from 183 in Q1 2019.
  • Funds reported $462M of Meridian Bioscience Inc stock for Q2 2019, down 34% quarter-over-quarter.
  • 34 funds opened new Meridian Bioscience Inc positions in Q2 2019 and 40 closed out, a net change of -6 holders.
  • The largest Meridian Bioscience Inc buyer in Q2 2019 was Assenagon Asset Management, an estimated $8.58M added.
  • The largest Meridian Bioscience Inc seller in Q2 2019 was Vaughan Nelson Investment Management, an estimated $25.8M sold.

Based on aggregated 13F filings for Q2 2019.